A new lead against resistant bacteria.

Scientists identified abaucin, a compound active against Acinetobacter baumannii, with help from deep learning.

Experimental · source published 2023-05-25

The human problem

Antibiotic resistance narrows the options for treating infections.

Screening compounds experimentally is resource intensive.

A model prioritized compounds for laboratory testing.

Abaucin showed activity in experiments, including a mouse wound infection model.

A possible starting point for developing a narrow-spectrum antibiotic.

Preclinical evidence. Human safety and efficacy are not established.

Investigate mechanism, optimize the compound, and assess safety before clinical translation.

Source history & evidence assessment

Legacy source check; no named human reviewer is recorded in this projection.

Maturity describes the tested or operational setting. Confidence describes support for the particular claim; one does not determine the other.

Institutions: McMaster University & MIT

Editorial connections between distinct settings and results; these links do not imply replication.

No corrections recorded.